ArticleNature biomedical engineering2023
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Article in Nature biomedical engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector forMolecular therapy. Advances · 2026Article
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production.Molecular therapy. Advances · 2026Article
- Engineering high-titer lentiviral vectors for robust expression of RNA-based gene circuits.bioRxiv : the preprint server for biology · 2026Article
- Universal strategy to generate lentiviral vectors encoding lethal proteins.Molecular therapy. Advances · 2026Article
- Generation and Characterization of CAR-T Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Gamma-retrovirus design for efficacious microRNA-mediated gene knock-down and protein co-expression without compromising titers.NAR molecular medicine · 2025Article
- Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells.Molecular therapy. Methods & clinical development · 2025Article
- Multimodal Nanoplasmonic and Fluorescence Imaging for Simultaneous Monitoring of Single-Cell Secretory and Intracellular Dynamics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.MedComm · 2025Article
- OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress.Frontiers in oncology · 2025Review
- Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.Frontiers in immunology · 2025Article
- Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches.International journal of nanomedicine · 2025Review
- Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.Journal for immunotherapy of cancer · 2024Article
- Engineered CD4 T cells for in vivo delivery of therapeutic proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- shRNA Targeting Lentiviral Vector Minus-Strand Product Improves the Viral Titer During Viral Packaging.Molecular biotechnology · 2024Article
- Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.The Journal of clinical investigation · 2024Article
- Mitochondrial outer membrane protein MTUS1/ATIP1 exerts antitumor effects through ROS-induced mitochondrial pyroptosis in head and neck squamous cell carcinoma.International journal of biological sciences · 2024Article
- Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vectors that facilitate the engineering of T cells that can better harness endogenous immunity and overcome suppressive barriers in the tumour microenvironment would help improve the safety and efficacy of T-cell therapies for more patients. Here we report the design, production and applicability, in T-cell engineering, of a lentiviral vector leveraging an antisense configuration and comprising a promoter driving the constitutive expression of a tumour-directed receptor and a second promoter enabling the efficient activation-inducible expression of a genetic payload. The vector allows for the delivery of a variety of genes to human T cells, as we show for interleukin-2 and a microRNA-based short hairpin RNA for the knockdown of the gene coding for haematopoietic progenitor kinase 1, a negative regulator of T-cell-receptor signalling. We also show that a gene encoded under an activation-inducible promoter is specifically expressed by tumour-redirected T cells on encountering a target antigen in the tumour microenvironment. The single two-gene-encoding vector can be produced at high titres under an optimized protocol adaptable to good manufacturing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.